Latest Asx News

RAS Technology Holdings Limited reported a robust 31% revenue increase to $21.3 million in FY25, achieving its first after-tax profit following a strategic acquisition in Hong Kong that expanded its Asian footprint and recurring revenue.

Cosmos Exploration’s optioned entity, EAU Lithium, has agreed to acquire a fully constructed pilot plant from Vulcan Energy Resources to advance lithium extraction testing in Bolivia. This move strengthens Cosmos’ strategic foothold in one of the world’s most promising lithium regions.

Westgold Resources Limited has announced an on-market buy-back of up to 47.18 million shares, signaling a strategic move to manage capital and potentially boost shareholder value.

New Age Exploration has verified key geological features at its Wagyu Gold Project, aligning it with the prolific Hemi mineral corridor and paving the way for expanded drilling.

Ramsay Health Care has announced a fully franked ordinary dividend of AUD 0.40 per share for the six months ending June 2025, signaling steady returns for shareholders.

Greatland Resources Limited has reported a robust unaudited FY2025 result, generating $337.3 million net profit after tax from seven months of Telfer gold-copper mine operations, alongside a successful ASX listing and strong cash flow.

RPM Automotive Group reported a mixed FY25 with a slight revenue decline but improved profitability and launched a tyre recycling initiative signaling a strategic shift.

Raiz Invest reported robust FY25 results with 15% revenue growth and a near break-even net loss, underpinned by strong customer and funds growth. The fintech’s strategic innovations and partnerships set a positive tone for FY26.

Control Bionics Limited has announced a $2.06 million non-renounceable rights issue to fund the commercial expansion of its NeuroStrip device and bolster NeuroNode operations. The capital raise is underwritten to approximately $1.15 million by major shareholders and strategic partners.

Westgold Resources Limited has announced a 3 cent per share final dividend for the financial year ending June 2025, payable in October. The dividend is unfranked, reflecting the company’s current tax position.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Pengana Capital Group reported a strong turnaround in FY 2025 profitability, driven by a surge in private credit funds under management and successful new product launches. The firm’s strategic shift towards private markets is reshaping its revenue profile and balance sheet strength.